289 related articles for article (PubMed ID: 26437858)
1. Model of fibrolamellar hepatocellular carcinomas reveals striking enrichment in cancer stem cells.
Oikawa T; Wauthier E; Dinh TA; Selitsky SR; Reyna-Neyra A; Carpino G; Levine R; Cardinale V; Klimstra D; Gaudio E; Alvaro D; Carrasco N; Sethupathy P; Reid LM
Nat Commun; 2015 Oct; 6():8070. PubMed ID: 26437858
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates That the Dnajb1-Prkaca Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma.
Engelholm LH; Riaz A; Serra D; Dagnæs-Hansen F; Johansen JV; Santoni-Rugiu E; Hansen SH; Niola F; Frödin M
Gastroenterology; 2017 Dec; 153(6):1662-1673.e10. PubMed ID: 28923495
[TBL] [Abstract][Full Text] [Related]
3.
Kastenhuber ER; Lalazar G; Houlihan SL; Tschaharganeh DF; Baslan T; Chen CC; Requena D; Tian S; Bosbach B; Wilkinson JE; Simon SM; Lowe SW
Proc Natl Acad Sci U S A; 2017 Dec; 114(50):13076-13084. PubMed ID: 29162699
[TBL] [Abstract][Full Text] [Related]
4. BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA.
Hirsch TZ; Negulescu A; Gupta B; Caruso S; Noblet B; Couchy G; Bayard Q; Meunier L; Morcrette G; Scoazec JY; Blanc JF; Amaddeo G; Nault JC; Bioulac-Sage P; Ziol M; Beaufrère A; Paradis V; Calderaro J; Imbeaud S; Zucman-Rossi J
J Hepatol; 2020 May; 72(5):924-936. PubMed ID: 31862487
[TBL] [Abstract][Full Text] [Related]
5. Fibrolamellar Hepatocellular Carcinoma: Mechanistic Distinction From Adult Hepatocellular Carcinoma.
Riggle KM; Turnham R; Scott JD; Yeung RS; Riehle KJ
Pediatr Blood Cancer; 2016 Jul; 63(7):1163-7. PubMed ID: 26990031
[TBL] [Abstract][Full Text] [Related]
6. DNAJB1-PRKACA is specific for fibrolamellar carcinoma.
Graham RP; Jin L; Knutson DL; Kloft-Nelson SM; Greipp PT; Waldburger N; Roessler S; Longerich T; Roberts LR; Oliveira AM; Halling KC; Schirmacher P; Torbenson MS
Mod Pathol; 2015 Jun; 28(6):822-9. PubMed ID: 25698061
[TBL] [Abstract][Full Text] [Related]
7. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma.
Honeyman JN; Simon EP; Robine N; Chiaroni-Clarke R; Darcy DG; Lim II; Gleason CE; Murphy JM; Rosenberg BR; Teegan L; Takacs CN; Botero S; Belote R; Germer S; Emde AK; Vacic V; Bhanot U; LaQuaglia MP; Simon SM
Science; 2014 Feb; 343(6174):1010-4. PubMed ID: 24578576
[TBL] [Abstract][Full Text] [Related]
8. A genomic case study of mixed fibrolamellar hepatocellular carcinoma.
Griffith OL; Griffith M; Krysiak K; Magrini V; Ramu A; Skidmore ZL; Kunisaki J; Austin R; McGrath S; Zhang J; Demeter R; Graves T; Eldred JM; Walker J; Larson DE; Maher CA; Lin Y; Chapman W; Mahadevan A; Miksad R; Nasser I; Hanto DW; Mardis ER
Ann Oncol; 2016 Jun; 27(6):1148-1154. PubMed ID: 27029710
[TBL] [Abstract][Full Text] [Related]
9. The DNAJB1-PRKACA chimera: Candidate biomarker and therapeutic target for fibrolamellar carcinomas.
Reid LM; Sethupathy P
Hepatology; 2016 Feb; 63(2):662-4. PubMed ID: 26505878
[No Abstract] [Full Text] [Related]
10. DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma.
Vyas M; Hechtman JF; Zhang Y; Benayed R; Yavas A; Askan G; Shia J; Klimstra DS; Basturk O
Mod Pathol; 2020 Apr; 33(4):648-656. PubMed ID: 31676785
[TBL] [Abstract][Full Text] [Related]
11. Liver cancer: A model of fibrolamellar carcinoma.
Patman G
Nat Rev Gastroenterol Hepatol; 2015 Dec; 12(12):672. PubMed ID: 26503883
[No Abstract] [Full Text] [Related]
12. Enhanced cAMP-stimulated protein kinase A activity in human fibrolamellar hepatocellular carcinoma.
Riggle KM; Riehle KJ; Kenerson HL; Turnham R; Homma MK; Kazami M; Samelson B; Bauer R; McKnight GS; Scott JD; Yeung RS
Pediatr Res; 2016 Jul; 80(1):110-8. PubMed ID: 27027723
[TBL] [Abstract][Full Text] [Related]
13. DLK1 as a potential target against cancer stem/progenitor cells of hepatocellular carcinoma.
Xu X; Liu RF; Zhang X; Huang LY; Chen F; Fei QL; Han ZG
Mol Cancer Ther; 2012 Mar; 11(3):629-38. PubMed ID: 22238367
[TBL] [Abstract][Full Text] [Related]
14. Unique genomic profile of fibrolamellar hepatocellular carcinoma.
Cornella H; Alsinet C; Sayols S; Zhang Z; Hao K; Cabellos L; Hoshida Y; Villanueva A; Thung S; Ward SC; Rodriguez-Carunchio L; Vila-Casadesús M; Imbeaud S; Lachenmayer A; Quaglia A; Nagorney DM; Minguez B; Carrilho F; Roberts LR; Waxman S; Mazzaferro V; Schwartz M; Esteller M; Heaton ND; Zucman-Rossi J; Llovet JM
Gastroenterology; 2015 Apr; 148(4):806-18.e10. PubMed ID: 25557953
[TBL] [Abstract][Full Text] [Related]
15. Novel protein kinase cAMP-Activated Catalytic Subunit Alpha (PRKACA) inhibitor shows anti-tumor activity in a fibrolamellar hepatocellular carcinoma model.
Toyota A; Goto M; Miyamoto M; Nagashima Y; Iwasaki S; Komatsu T; Momose T; Yoshida K; Tsukada T; Matsufuji T; Ohno A; Suzuki M; Ubukata O; Kaneta Y
Biochem Biophys Res Commun; 2022 Sep; 621():157-161. PubMed ID: 35839742
[TBL] [Abstract][Full Text] [Related]
16. Hepatic cancer stem cell marker granulin-epithelin precursor and β-catenin expression associate with recurrence in hepatocellular carcinoma.
Cheung PF; Cheung TT; Yip CW; Ng LW; Fung SW; Lo CM; Fan ST; Cheung ST
Oncotarget; 2016 Apr; 7(16):21644-57. PubMed ID: 26942873
[TBL] [Abstract][Full Text] [Related]
17. EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma.
Terris B; Cavard C; Perret C
J Hepatol; 2010 Feb; 52(2):280-1. PubMed ID: 20006402
[TBL] [Abstract][Full Text] [Related]
18. Hepatic adenomas with synchronous or metachronous fibrolamellar carcinomas: both are characterized by LFABP loss.
Graham RP; Terracciano LM; Meves A; Vanderboom PM; Dasari S; Yeh MM; Torbenson MS; Cruise MW
Mod Pathol; 2016 Jun; 29(6):607-15. PubMed ID: 27015136
[TBL] [Abstract][Full Text] [Related]
19. Isolation and characterization of hepatic cancer cells with stem-like properties from hepatocellular carcinoma.
Tomuleasa C; Soritau O; Rus-Ciuca D; Pop T; Todea D; Mosteanu O; Pintea B; Foris V; Susman S; Kacsó G; Irimie A
J Gastrointestin Liver Dis; 2010 Mar; 19(1):61-7. PubMed ID: 20361077
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of WWP1 promotes tumorigenesis and predicts unfavorable prognosis in patients with hepatocellular carcinoma.
Zhang XF; Chao J; Pan QZ; Pan K; Weng DS; Wang QJ; Zhao JJ; He J; Liu Q; Jiang SS; Chen CL; Zhang HX; Xia JC
Oncotarget; 2015 Dec; 6(38):40920-33. PubMed ID: 26506518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
